Rena J. Eudy-Byrne, Ph.D.

Senior Scientist II

Rena joined Metrum in November 2015 after completing her Ph.D. in Biomedical Engineering at the University of Connecticut. Her dissertation work included extending a systems pharmacology model of bone and osteoporosis to be relevant for the development new therapies. Part of this work included linking simulated changes in bone mineral density to a hazard model of fracture in a Bayesian framework in order to predict the probability of fracture in osteoporosis patients. Analysis tools for establishing a priori identifiability of target-mediated drug disposition and other indirect response-type models were also part of this larger work. Rena brings 5 years of industry experience to the team, including work in preclinical development in metabolic systems and neuroscience and using systems pharmacology models to inform clinical decisions.

Recent publications by this scientist

Population pharmacokinetics of nerandomilast in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis

March 18, 2026

Population pharmacokinetics of nerandomilast in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis

Megan Pane1, Curtis Johnston1∗, Rena Eudy-Byrne1, Tyler Dunlap1, Nikolas Onufrak2∗, Sonja Hartmann2∗, Steve Choy21Metrum Research Group, Boston, MA, U.S.A.,2Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, U.S.A.

∗Affiliation during time of analysis

Mechanism of Action
• Nerandomilast (JASCAYD®) is an orally administered, preferential inhibitor of the
phosphodiesterase-4B (PDE4B) isoenzyme
• PDE4B hydrolyzes and inactivates cyclic adenosine monophosphate
Therapeutic Indication
• Approved by the U.S. FDA and China’s CDE for the treatment of idiopathic pul-
monary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)
• IPF is a specific type of interstitial lung disease (ILD) and PPF is associated with a
subset of ILDs distinct from IPF
• Both IPF and PPF lead to lung scarring that progresses over time, with a median
survival time of 3-5 years
Chemical and Metabolic Properties
• Nerandomilast (R-enantiomer) contains a chiral sulfoxide group and undergoes a
minor level of metabolic chiral inversion following oral administration
• The resulting S-enantiomer is pharmacologically inactive
• Both nerandomilast and the S-enantiomer were characterized in this analysis

Download PDF

Integrated Two‑Analyte Population Pharmacokinetics Model of Patritumab Deruxtecan (HER3‑DXd) Monotherapy in Patients with Solid Tumors

June 17, 2025

This work illustrates how integrated population PK modeling of antibody-conjugated payload and free payload analytes for an ADC can inform development strategies for targeted therapies—particularly in complex oncology settings.

Read Article

Data Gaps, Model Mishaps: Quantifying the Impact of Missing Pharmacometrics Data on Pharmacodynamic Projections.

December 6, 2024

Presented at ACoP 2024. In this analysis aimed to evaluate the ability to estimate robust population PD parameters and a landmark endpoint in different scenarios. In the primary workflow different levels of missing PK data were tested. Additionally, varying degrees of of individual-level and residual variability were tested. Finally, scenarios with smaller populations were tested. In all scenarios, PD parameters and endpoints could be estimated with adequate accuracy and precision.

Download PDF